VYNE Therapeutics (VYNE) Long-Term Investments (2016 - 2019)

VYNE Therapeutics' Long-Term Investments history runs 4 years deep, the most recent figure standing at $2.0 million for Q3 2019.

• Quarterly Long-Term Investments changed N/A year-over-year to $2.0 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $2.0 million (changed N/A YoY) and the FY2017 annual result came in at $3.0 million, down 71.42% from the prior year.
• Long-Term Investments was $2.0 million for Q3 2019 at VYNE Therapeutics, down from $10.4 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $20.7 million in Q1 2018 and bottomed at $2.0 million in Q3 2019.
• A 4-year average of $9.3 million and a median of $10.4 million in 2016 frame the typical range for Long-Term Investments.
• Peak annual rise in Long-Term Investments reached 71.42% in 2017, while the deepest fall reached 71.42% in 2017.
• VYNE Therapeutics' Long-Term Investments stood at $10.4 million in 2016, then sank by 71.42% to $3.0 million in 2017, then soared by 250.07% to $10.4 million in 2018, then tumbled by 80.78% to $2.0 million in 2019.
• Business Quant data shows VYNE's Long-Term Investments at $2.0 million in Q3 2019, $10.4 million in Q2 2018, and $20.7 million in Q1 2018.